A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Grants and Contracts Details

StatusActive
Effective start/end date10/10/188/16/23

Funding

  • Celgene International II Sarl: $39,863.00